Astellas Financial Statements From 2010 to 2024
| ALPMF Stock | USD 10.50 0.13 1.25% |
Check Astellas Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Astellas Pharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . Astellas financial statements analysis is a perfect complement when working with Astellas Pharma Valuation or Volatility modules.
Astellas |
Astellas Pharma Company Current Valuation Analysis
Astellas Pharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Astellas Pharma Current Valuation | 26.19 B |
Most of Astellas Pharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Astellas Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Astellas Pharma has a Current Valuation of 26.19 B. This is 82.32% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The current valuation for all United States stocks is 57.52% lower than that of the firm.
Astellas Pharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Astellas Pharma's current stock value. Our valuation model uses many indicators to compare Astellas Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Astellas Pharma competition to find correlations between indicators driving Astellas Pharma's intrinsic value. More Info.Astellas Pharma is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers reporting about 0.73 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Astellas Pharma is roughly 1.38 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Astellas Pharma's earnings, one of the primary drivers of an investment's value.About Astellas Pharma Financial Statements
Astellas Pharma stakeholders use historical fundamental indicators, such as Astellas Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Astellas Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Astellas Pharma's assets and liabilities are reflected in the revenues and expenses on Astellas Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Astellas Pharma. Please read more on our technical analysis and fundamental analysis pages.
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan. ASTELLAS PHARMA operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 14522 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Astellas Pink Sheet
Astellas Pharma financial ratios help investors to determine whether Astellas Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Astellas with respect to the benefits of owning Astellas Pharma security.